Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade

With the increasing use of immune checkpoint inhibitors (ICIs) in combination regimens and in earlier stages of advanced melanoma, the effective management of immune-related adverse events (irAEs) is key to balancing immunotherapy efficacy and toxicity. Conflicting evidence exists on possible detrim...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	OncoImmunology
المؤلفون الرئيسيون:	Nina B. Curkovic, Rebecca Irlmeier, Xue Bai, Can Cui, Fei Ye, Hannah R. Burnette, Aleigha R. Lawless, Juliane Andrade Czapla, Ryan Sullivan, Douglas B. Johnson
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Taylor & Francis Group 2025-12-01
الموضوعات:	Immune checkpoint inhibitor immune-related adverse event - irAE immunosuppression immunotherapy
الوصول للمادة أونلاين:	https://www.tandfonline.com/doi/10.1080/2162402X.2025.2494433